A1 Refereed original research article in a scientific journal

COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes A multicontinental cohort study




AuthorsHuespe Ivan A., Ferraris Augusto, Lalueza Antonio, Valdez Pascual R., Peroni Maria L., Cayetti Luis A., Mirofsky Matias A., Boietti Bruno, Gómez-Huelgas Ricardo, Casas-Rojo José M., Antón-Santos Juan M., Núñez-Cortés Jesús M., Lumbreras Carlos, Ramos-Rincón Jose-Manuel, Barrio Noelia G., Pedrera-Jiménez Miguel, Martin-Escalante María D., Ruiz Francisco R., Onieva-García María Á., Toso Carlos R., Risk Marcelo R., Klén Riku, Pollán Javier A., Gómez-Varela David

PublisherWiley

Publication year2023

JournalJournal of Medical Virology

Journal name in sourceJournal of medical virology

Journal acronymJ Med Virol

Volume95

Issue5

ISSN0146-6615

eISSN1096-9071

DOIhttps://doi.org/10.1002/jmv.28786

Web address https://doi.org/10.1002/jmv.28786

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/179760905


Abstract
The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9-24), compared to 19.5% (95% CI: 19-20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89-1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56-0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1-5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23-0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20-0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41-1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6-1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2025-27-03 at 21:50